DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
2 ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System Visit Post
3 Which Pipeline Therapy is Expected to Capture the Eyeballs in the Phenylketonuria Market? Visit Post
4 Shape Therapeutics-Roche's Deal; AllStripes Raises $50M; Datavant-Real Chemistry's Partnership; BlueWillow's Nasal Vaccine Visit Post
5 Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea's Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer Visit Post
6 Primary Hyperoxaluria Market Size Observes Growth with a Substantial CAGR Visit Post
7 Angelman syndrome Pipeline: Unmet needs call for a robust pipeline Visit Post
8 Essential Demands Impinge the Evolving Adult-onset Still’s Disease Treatment Market Visit Post
9 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
10 Rising Awareness, Key Companies, Emerging Therapies? What is Shaping the Alagille Syndrome Market Visit Post
11 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
12 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
13 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
14 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
15 Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market? Visit Post
16 Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere? Visit Post
17 A Royal Disease: Hemophilia Visit Post
18 Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’? Visit Post
19 What are the Market Drivers Fueling the Rare Disease Market? Visit Post
20 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
21 Emerging Research Continues To Transform Erythropoietic Protoporphyria Market Outlook Visit Post
22 Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities Visit Post
23 The Paradox of Rare: Chalking out Challenges in the Rare Disease Market Visit Post
24 Limited Therapies in the Rare Disease Pipeline: Watch out for Rare Indications that Calls Out for Novel Therapies Visit Post
25 A Bleak Pipeline and Lack of Approved Treatment Clouds the Hemophagocytic Lymphohistiocytosis Market Size Growth Visit Post
26 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
27 Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder Visit Post
28 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
29 Unmet Needs and Emerging Trends in the Acute Respiratory Distress Syndrome Market Landscape Visit Post
30 Top 10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment Landscape Visit Post
31 8 Of The Most Common Foods Allergies - Do You Have One? Visit Post
32 21 of the most common questions about Epilepsy Visit Post
33 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
34 Ever-evolving Market Dynamics of Epilepsy – a silver lining! Visit Post
35 Key Pharma Players Transforming the Complement 3 Glomerulopathy Market Landscape Visit Post
36 Argininosuccinic Aciduria Market Awaits Innovative Treatment Expected To Launch In The Next Decade Visit Post
37 Pharma Players Line Up To Launch Novel Therapies Fueling Epidermolysis Bullosa Market Size Visit Post
38 Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19 Visit Post
39 Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing Visit Post
40 What Does The Acromegaly Pipeline Have Up In Its Sleeve? Visit Post
41 The Rarity Of Dravet Syndrome: Challenges, and Treatments Visit Post
42 Sanofi acquires Principia; FDA's Nod to Roche's Enspryng; BMS, Dragonfly's Licensing Deal Visit Post
43 FDA's Ok to Roche's Oral SMA Therapy; Roche's Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem Visit Post
44 A Complex Chromosomal Abberation Called Adrenoleukodystrophy Visit Post
45 AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid's DMD gene therapy trial Visit Post
46 In Search for a Curative Treatment Option for Duchenne Muscular Dystrophy Visit Post
47 Is the cure for Duchenne Muscular Dystrophy in the pipeline? Visit Post
48 Is the cure for Huntington’s disease on the horizon? Visit Post
49 Avrobio taps Magenta’s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic, Visit Post
50 Anaphylaxis: A Rare Disease Visit Post
51 Angelman syndrome: A Rare Genetic Disorder Visit Post
52 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
53 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
54 Fragile X Syndrome Market Visit Post
55 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
56 Gaucher disease Market Analysis: Rich Pipeline Drives the Market Ahead Visit Post
57 Are Rare Diseases truly Rare? Visit Post
58 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval Visit Post
59 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
60 AbbVie Sells bonds to Fund Allergan takeover Visit Post
61 Beta-Thalassemia Pharmacological Therapies Visit Post
62 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
63 Non-Small Cell Lung Cancer Market: Treatments and Market Forecast Visit Post
64 EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline Visit Post
65 Batten Disease Market: Barriers and Growth Opportunities Visit Post
66 EU’s labels Nirogacestat an Orphan drug; FDA Approves First Smallpox, Monkeypox Vaccine; Evotec and Takeda collaborates to discover clinical candidates Visit Post
67 Hyperthyroidism Treatment Market and Drugs Visit Post
68 Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial Visit Post
69 How Spinal Muscular Atrophy Therapies transform market? Visit Post
70 EU approval for Imbruvica; Pharming licenses orphan drug Visit Post
71 Niemann–Pick disease type C Therapeutics Market Visit Post
72 Myasthenia gravis Market Outlook Visit Post
73 Myasthenia Gravis Awareness Month Visit Post
74 Pompe Disease Scenario in Eastern Europe Visit Post
75 Pompe Disease Emerging Markets Visit Post
76 Scoliosis Awareness Month Visit Post
77 The era of Gene therapy, and the Billion Dollar tag Visit Post
78 Pompe Disease Treatment Market Visit Post
79 Pompe Disease Market Visit Post
80 Origins of the depressive behaviour in Huntington's disease Visit Post
81 World Multiple Sclerosis Day Visit Post
82 What is causing a rise in Autism rate? Visit Post
83 Meet the World's most expensive drug: Zolgensma Visit Post
84 Pulmonary Arterial Hypertension Therapies Visit Post
85 AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration Visit Post
86 Notizia Visit Post
87 Spinal Muscular Atrophy Market Visit Post
88 Spinal Muscular Atrophy: Current and Emerging Therapies Visit Post
89 Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42% Visit Post
90 Autism Spectrum Disorder Visit Post
91 Can Spinal Muscular Atrophy be treated by Protease Inhibitors? Visit Post
92 World Haemophilia Day Visit Post
93 Beta Interferons prolongs life in Multiple Sclerosis Visit Post
94 New Osteoporosis Drug promises to rebuild Bone Visit Post
95 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
96 Notizia Visit Post
97 What can be the scope of Medical Marijuana? Visit Post
98 Notizia Visit Post
99 Boys are more likely to have autism! Visit Post
100 Multiple Myeloma Day Visit Post
101 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
102 Cost ineffective Orphan Drugs limit the access Visit Post
103 Rare Disease Day Visit Post
104 Notizia Visit Post
105 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
106 Myasthenia Gravis Visit Post
107 Neuroendocrine Tumors (NETs) Visit Post
108 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
109 Notizia Visit Post
110 Artificial Intelligence face-scanning app spots signs of rare genetic disorders Visit Post
111 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
112 Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal Visit Post
113 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
114 Notizia Visit Post
115 Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates Visit Post
116 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
117 Calciphylaxis: Rare Yet Potentially Fatal Visit Post
118 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
119 Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives Visit Post
122 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
123 Notizia Visit Post
124 Companion Diagnostics Visit Post
125 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
126 Snippet Visit Post
127 Snippet Visit Post
128 Notizia Visit Post
129 Neuroendocrine tumors (NETs): The complex group of tumors Visit Post
130 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
131 Orphan Drug Act and Its Criticism Visit Post
132 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
133 Regulatory Visit Post
134 Commercial Visit Post
135 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
136 Progenics got FDA Approval; Curcumin to cancer cells Visit Post
137 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window Visit Post
138 Niemann-Pick disease type C (NPC) -A Rare Cognitive Decline Indication Visit Post
139 Snippet : Acute lymphoblastic leukemia Visit Post
140 Predicting risk of Acute Myeloid Leukemia (AML) in healthy individuals Visit Post
141 NF-κB Inhibitors- A Promising Future Visit Post
142 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
143 Hematopoietic Stem Cell Transplantation Visit Post
144 Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment Visit Post
145 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
146 Business Cocktail Visit Post
147 Notizia Visit Post
148 Business Cocktail Visit Post
149 Notizia Visit Post
150 Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market Visit Post
151 Familial Amyloid Polyneuropathy – An uncommon medical condition Visit Post
152 Hereditary Angioedema (HAE) – Active drug pipeline Visit Post
153 Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Upcoming Therapies Visit Post
154 Gaucher Disease: “Rare Disorder with High Unmet Needs” Visit Post
155 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
156 Bubble Boy Syndrome (ADA-SCID) - A Rare Immunodeficiency Disorder Visit Post
157 Wiskott - Aldrich syndrome – a rare X-linked disorder Visit Post
158 Metachromatic Leukodystrophy (MLD): A Rare Indication with great unmet medical need Visit Post
159 C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents Visit Post
160 Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD Visit Post
161 Amyotrophic Lateral Sclerosis (ALS) a fatal disease! Visit Post
162 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
163 Friedrich's ataxia: Rare disease Visit Post
164 Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO Visit Post
165 Progressive Supranuclear Palsy– A neurodegenerative disorder Visit Post
166 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
167 Hemophilia A- Market Scenario Visit Post
168 Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation Visit Post
169 ALCMI, ALCF and Scancell partner; Sun unloads Ohm Labs plants; Takeda and Ovid join; Guardant and MD Anderson collaborate; Glooko and Ascensia integrate Visit Post
170 U.K. weighs drug rationing; Applying Digital; FDA slaps Florida Visit Post
171 Fragile X syndrome: X-linked mental retardation and macroorchidism Visit Post
172 Systemic Lupus Erythematosus: An autoimmune disease Visit Post
173 EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs Visit Post
174 High Risk Smoldering Multiple Myeloma Visit Post
175 Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant Visit Post
176 Idiopathic Pulmonary Fibrosis: Recent Scenario Visit Post
177 Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika Visit Post
178 Sarepta’s Unusual Journey Visit Post
179 Merck launches Biosimilars, ABITEC announces extension, First human clinical trial, FDA awards 2grants, Corden Pharma Expands, Juniper Pharma Services Offers Visit Post
180 Liquid Biopsy: Revolutionary Technique for Cancer Diagnosis Visit Post
181 The Snippet: The Success of Cannabidiol Visit Post
182 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
183 Cervical Cancer: Current Scenario Visit Post
184 FDA Approves Sarepta’s Muscular Dystrophy Drug after Months of Debate Visit Post
185 PI3Kγ- a molecular switch that controls immune suppression Visit Post
186 Graft vs Host Disease (GVHD): Treatment approaches and Trends Visit Post
187 Roche's drug; Cancer drugs risk; FDA norms; Takeda sets deal Visit Post
188 Treatment for esophageal cancer; FDA bans soaps; Dr Reddy's Launches; Cipla Gets Approval Visit Post
189 Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug Visit Post
190 Denali's Impressive Research Portfolio Visit Post
191 The Curious Case of CRISPR Technology Visit Post
192 Pharm Delve Cognizance Visit Post
193 Spinal Muscular Atrophy Emerging therapies Visit Post
194 A promising immune-stimulating target Visit Post
195 Anticoagulants-Market Insights; Drugs Sales Forecast (VTE & AF) Visit Post
196 Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2020 Visit Post
197 Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
198 Hemophilia - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
199 Idiopathic pulmonary fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
200 Duchenne Muscular Dystrophy Market Visit Post
201 Acute Myeloid Leukemia- Market Insights, Epidemiology & Forecast Visit Post
202 PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 Visit Post
203 LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 - A DelveInsight Report Visit Post
204 Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast Visit Post
205 Zemplar Drug Insights, 2016 Visit Post
206   Pancreatic Cancer-Pipeline Insights, 2016 Visit Post
207 Rising of Orphan Drug Development Visit Post
208 Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 Visit Post
209 Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension Visit Post
210 Gene Therapy’s Emergence: The “New” approach for Huntington’s disease Visit Post
211 Global Hemophilia Market Visit Post